A citation-based method for searching scientific literature

Helen E Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala, Heather Allan, Gregory J Keir, Andrew Hayen, Wendy A Cooper, Annabelle M Mahar, Samantha Ellis, Sacha Macansh, Tamera J Corte. Eur Respir J 2017
Times Cited: 100







List of co-cited articles
664 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
56

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
54

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
54

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
43

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Andreas Guenther, Ekaterina Krauss, Silke Tello, Jasmin Wagner, Bettina Paul, Stefan Kuhn, Olga Maurer, Sabine Heinemann, Ulrich Costabel, María Asunción Nieto Barbero,[...]. Respir Res 2018
107
33

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.
Jürgen Behr, Michael Kreuter, Marius M Hoeper, Hubert Wirtz, Jens Klotsche, Dirk Koschel, Stefan Andreas, Martin Claussen, Christian Grohé, Henrike Wilkens,[...]. Eur Respir J 2015
130
32

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
985
31

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
28

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
598
27

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
144
22

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
210
22

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
876
21

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
539
21

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.
Ganesh Raghu, Shih-Yin Chen, Wei-Shi Yeh, Brad Maroni, Qian Li, Yuan-Chi Lee, Harold R Collard. Lancet Respir Med 2014
318
17

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Martin Kolb, Luca Richeldi, Jürgen Behr, Toby M Maher, Wenbo Tang, Susanne Stowasser, Christoph Hallmann, Roland M du Bois. Thorax 2017
115
16

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
641
16

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
Michael Kreuter, Jeff Swigris, David Pittrow, Silke Geier, Jens Klotsche, Antje Prasse, Hubert Wirtz, Dirk Koschel, Stefan Andreas, Martin Claussen,[...]. Respir Res 2017
79
18

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh,[...]. Lancet Respir Med 2018
383
14

Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
Michael Kreuter, Svenja Ehlers-Tenenbaum, Karin Palmowski, Jacques Bruhwyler, Ute Oltmanns, Thomas Muley, Claus Peter Heussel, Arne Warth, Martin Kolb, Felix J F Herth. PLoS One 2016
148
13

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry.
Giovanni Ferrara, Lisa Carlson, Andreas Palm, Jonas Einarsson, Cecilia Olivesten, Magnus Sköld. Eur Clin Respir J 2016
31
41

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
13

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever. Eur Respir J 2015
343
13

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
451
13

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
209
12

Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry.
Ian N Glaspole, Sally A Chapman, Wendy A Cooper, Samantha J Ellis, Nicole S Goh, Peter M Hopkins, Sacha Macansh, Annabelle Mahar, Yuben P Moodley, Eldho Paul,[...]. Respirology 2017
54
22

Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.
Evans R Fernández Pérez, Craig E Daniels, Darrell R Schroeder, Jennifer St Sauver, Thomas E Hartman, Brian J Bartholmai, Eunhee S Yi, Jay H Ryu. Chest 2010
271
12

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wim A Wuyts, Caroline Dahlqvist, Hans Slabbynck, Marc Schlesser, Natacha Gusbin, Christophe Compere, Sofie Maddens, Klaus-Uwe Kirchgaessler, Karen Bartley, Benjamin Bondue. BMJ Open Respir Res 2018
24
50

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Monika Zurkova, Eva Kriegova, Vitezslav Kolek, Vladimira Lostakova, Martina Sterclova, Vladimir Bartos, Martina Doubkova, Ilona Binkova, Michal Svoboda, Jana Strenkova,[...]. Respir Res 2019
38
31

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
882
11

Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry.
Emily C O'Brien, Michael T Durheim, Victoria Gamerman, Sandy Garfinkel, Kevin J Anstrom, Scott M Palmer, Craig S Conoscenti. BMJ Open Respir Res 2016
27
40

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
499
11

Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.
J W Song, S-B Hong, C-M Lim, Y Koh, D S Kim. Eur Respir J 2011
428
11

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Jonathan A Galli, Aloknath Pandya, Michelle Vega-Olivo, Chandra Dass, Huaqing Zhao, Gerard J Criner. Respirology 2017
80
12

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
151
10

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Gareth Hughes, Hannah Toellner, Helen Morris, Colm Leonard, Nazia Chaudhuri. J Clin Med 2016
96
10

Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.
Mark Fisher, Steven D Nathan, Christian Hill, Jade Marshall, Fred Dejonckheere, Per-Olof Thuresson, Toby M Maher. J Manag Care Spec Pharm 2017
43
23

Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.
Motoki Natsuizaka, Hirofumi Chiba, Koji Kuronuma, Mitsuo Otsuka, Kazumi Kudo, Mitsuru Mori, Masashi Bando, Yukihiko Sugiyama, Hiroki Takahashi. Am J Respir Crit Care Med 2014
224
10

Incidence and prevalence of idiopathic pulmonary fibrosis.
Ganesh Raghu, Derek Weycker, John Edelsberg, Williamson Z Bradford, Gerry Oster. Am J Respir Crit Care Med 2006
799
10

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Toby M Maher, Maria Molina-Molina, Anne-Marie Russell, Francesco Bonella, Stéphane Jouneau, Elena Ripamonti, Judit Axmann, Carlo Vancheri. BMC Pulm Med 2017
46
21

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
Helen E Jo, Ian Glaspole, Yuben Moodley, Sally Chapman, Samantha Ellis, Nicole Goh, Peter Hopkins, Greg Keir, Annabelle Mahar, Wendy Cooper,[...]. BMC Pulm Med 2018
37
27

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
104
10

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
430
10

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Michael Kreuter, Wim Wuyts, Elisabetta Renzoni, Dirk Koschel, Toby M Maher, Martin Kolb, Derek Weycker, Paolo Spagnolo, Klaus-Uwe Kirchgaessler, Felix J F Herth,[...]. Lancet Respir Med 2016
124
9

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Ganesh Raghu, Athol U Wells, Andrew G Nicholson, Luca Richeldi, Kevin R Flaherty, Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker-Herceg, David M Hansell. Am J Respir Crit Care Med 2017
106
9

Predicting survival across chronic interstitial lung disease: the ILD-GAP model.
Christopher J Ryerson, Eric Vittinghoff, Brett Ley, Joyce S Lee, Joshua J Mooney, Kirk D Jones, Brett M Elicker, Paul J Wolters, Laura L Koth, Talmadge E King,[...]. Chest 2014
212
9

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.
Ganesh Raghu, Valeria C Amatto, Jürgen Behr, Susanne Stowasser. Eur Respir J 2015
190
9

EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Martina Doubková, Jan Švancara, Michal Svoboda, Martina Šterclová, Vladimír Bartoš, Martina Plačková, Ladislav Lacina, Monika Žurková, Ilona Binková, Radka Bittenglová,[...]. Clin Respir J 2018
25
36

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.
Toby M Maher, Jeffrey J Swigris, Michael Kreuter, Marlies Wijsenbeek, Nicola Cassidy, Lucy Ireland, Judit Axmann, Steven D Nathan. Respiration 2018
27
33

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.
Ida Pesonen, Lisa Carlson, Nicola Murgia, Riitta Kaarteenaho, Carl Magnus Sköld, Marjukka Myllärniemi, Giovanni Ferrara. Multidiscip Respir Med 2018
13
69

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Carlo Albera, Ulrich Costabel, Elizabeth A Fagan, Marilyn K Glassberg, Eduard Gorina, Lisa Lancaster, David J Lederer, Steven D Nathan, Dominique Spirig, Jeff J Swigris. Eur Respir J 2016
85
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.